phase 2™ carb controller

a proven solution for carb control

description

Phase 2^{TM} is a proprietary, natural ingredient derived from the white kidney bean. Phase 2^{TM} is not a stimulant; it works by reducing the enzymatic digestion of dietary starches. Phase 2^{TM} has been clinically shown to reduce the digestion and absorption of dietary starches by up to 66%.

benefits

Phase $2^{\mathbb{M}}$ has been extensively studied; more than 14 clinical studies have been conducted in the past 15 years. Phase $2^{\mathbb{M}}$ is a market leader, and has been used successfully in multiple products worldwide.

Phase 2^{TM} white kidney bean extract has been reviewed by U.S. FDA to permit structure/function claims:

- "may reduce enzymatic digestion of dietary starch"
- "may assist in weight control when used with diet and exercise"

Additionly, Phase 2^{TM} has a license from the Natural Health Products Directorate of Canada, in which the following uses are authorized:

- "at 6 capsules (3000 mg) per day: Assists in weight management when used with a program of reduced intake of dietary calories and increased physical activity."
- "at 4–6 capsules (2,000–3,000 mg) per day: Provides support for healthy glucose metabolism following a carbohydrate rich meal."

Phase 2[™] has also been shown to have efficacy for pets. 88% of dogs in a multi-clinic study lost weight.²



advantages

- supports weight management
- structure/function claims support
- solvent-free
- self-affirmed GRAS status
- o made from U.S.-grown white kidney beans

recommended dosage

500–1500 mg per starchy meal. The amount required to inhibit alpha amylase enzyme from breaking down starches will vary based on amount of carbohydrate ingested.

product safety

Phase 2^{TM} is a natural extract with a good safety profile.

product form

Phase $2^{\text{\tiny M}}$ is sold as a powder and can be used in a variety of end formats.






¹Vinson JA, Kharrat HA, Shuta D. Investigation of an amylase inhibitor on human glucose absorption after starch consumption. The Open Nutraceuticals Journal, 2009;2:88-91.

²Rosenblatt S, Willauer C, Timmel A, Ota B. Use of commercial starch blockers in canine weight loss. Journal of the American Holistic Veterinary Medical Association, 2004;23(2):43-46.

These statements have not been approved by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.



regional centers

North America —

Kearny, NJ USA Tel: +1 800 526 0609 +1 201 246 2000

Europe — Poland Tel: +48 22 607 25 33

Europe — Spain Tel: +34 932 064 195

India — Maharashtra Tel: +91 22 61489696

Asia Pacific — Singapore Tel: +65 6775 5366

Middle East, Africa —

Istanbul, Turkey Tel: +90 216 538 08 00

Latin America — Mexico Tel: +52 55 52 76 6121

ashland.com/contact

- ® Registered trademark, Ashland or its subsidiaries, registered in various countries
- ™Trademark, Ashland or its subsidiaries, registered in various countries
- © 2019, Ashland / FNB18-110.1

The information contained in this brochure and the various products described are intended for use only by persons having technical skill and at their own discretion and risk after they have performed necessary technical investigations, tests and evaluations of the products and their uses. Certain end uses of these products may be regulated pursuant to rules or regulations governing medical devices, drug uses, or pesticidal or antimicrobial uses. It is the end user's responsibility to determine the applicability of such regulations to its products.

All statements, information, and data presented herein are believed to be accurate and reliable, but are not to be taken as a guarantee of fitness for a particular purpose, or representation, express or implied, for which seller assumes legal responsibility. No freedom to use any patent owned by Ashland, its subsidiaries, or its suppliers is to be inferred.

